



Medigard Ltd (ASX-MGZ)

Update and information

2017-11-29

Forward looking statements

This document may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Medigard about circumstances and events that have not yet taken place. Although Medigard believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Medigard that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

In a snapshot over nearly 20 years

Value and prospects

Medigard from 1999 to 2017

The way we see it now

1999

2017

In a snapshot in 2017

capitalisation
A\$m

100m

30m

3m

MGZ
~\$2.5m

Listed in
2004

Average ASX
Biotechnology
company ~
\$113m (out of
119)

Not to scale

Medigard's reason for being

Medigard started as a medical technology (medical device) innovation and commercialisation company :-

- to make people's lives better (and safer); and
- to make money for shareholders through inventions

But 20 years later requires us to look at different problems and state-of-the-art technology

The Board of Medigard has been investigating further avenues to have Medigard reach the heights that would reward stakeholders.

Through the review of business and technology opportunities Medigard has engaged with Dr Dixon and his Melbourne-based biotechnology team.

Medigard's Board is developing a strategy and plans to revitalise the company.

But it needs time, skill and experience

Potential rewards

Non-financial rewards

New medical treatments

Financial upsides

A financial return for shareholders

Looking forward

Stay tuned